Supply shortages of Cerezyme and Fabrazyme - priority access for patients most in need of treatment recommended

View source ↗

Summary

EMA recommends priority access to Cerezyme and Fabrazyme during supply shortages to ensure treatment for patients most in need.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease
• Gaucher Disease

Drugs mentioned

• CEREZYME (imiglucerase)
• FABRAZYME (Agalsidase beta)